ISCO director receives new stock option awards

International Stem Cell CORP director Don Wright received new stock option awards as compensation.

Rhea-AI Filing Summary

International Stem Cell CORP director Don Wright received new stock option awards as compensation. On June 11, 2026, he was granted options to buy 182,584 shares of common stock at an exercise price of $0.178 per share, expiring on June 11, 2036. The shares underlying this option vest on the earlier of June 11, 2027 or the next annual stockholder meeting after the grant date.

He was also granted options for 30,000 shares at an exercise price of $0.170 per share, also expiring on June 11, 2036. The shares underlying this option vest in equal quarterly increments through June 11, 2027, starting on September 11, 2026. These are awards, not open‑market purchases or sales.

Insider Trade Summary

Grant/Award: 212,584 shares

Grant/Award 2 txns

Insider Don Wright

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	30,000	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	182,584	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 212,584 contracts (Direct)

Footnotes (2)

1. F1. The shares underlying such option shall vest on the earlier of (a) June 11, 2027, or (b) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant.
2. F2. The shares underlying such option shall vest in equal quarterly increments through June 11, 2027, with the first increment vesting on September 11, 2026.

Key Figures

Option grant size 1: 182,584 options Exercise price 1: $0.178 per share Option grant size 2: 30,000 options +4 more

7 metrics

Option grant size 1 182,584 options Granted June 11, 2026 to buy common stock

Exercise price 1 $0.178 per share Conversion/exercise price for 182,584-share option

Option grant size 2 30,000 options Granted June 11, 2026 to buy common stock

Exercise price 2 $0.170 per share Conversion/exercise price for 30,000-share option

Expiration date June 11, 2036 Expiration for both option grants

Single-date vesting condition June 11, 2027 Latest vesting date or earlier next annual meeting for 182,584-share option

Quarterly vesting start September 11, 2026 First quarterly vesting date for 30,000-share option

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vest in equal quarterly increments, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 0.1780"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-11T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest in equal quarterly increments financial

"The shares underlying such option shall vest in equal quarterly increments through June 11, 2027"

annual meeting of the Issuer's stockholders financial

"on the earlier of (a) June 11, 2027, or (b) the date of the next annual meeting of the Issuer's stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Don Wright do in this International Stem Cell (ISCO) Form 4?

Don Wright received two stock option awards, gaining rights to buy common shares at fixed prices. These are compensation grants, not open‑market trades, and give him potential future ownership if the options vest and are exercised.

How many stock options did Don Wright receive from ISCO and at what prices?

He received options on 182,584 shares at an exercise price of $0.178 and options on 30,000 shares at $0.170. Both grants relate to International Stem Cell common stock and provide the right to buy shares at those prices.

When do Don Wright’s new ISCO stock options vest?

The 182,584-share option vests on the earlier of June 11, 2027 or the next annual stockholder meeting after the grant. The 30,000-share option vests in equal quarterly increments through June 11, 2027, starting on September 11, 2026.

When do Don Wright’s ISCO stock options expire?

Both stock option grants expire on June 11, 2036. After that date, any unexercised options lapse and can no longer be used to purchase International Stem Cell common stock at the stated exercise prices.

Are Don Wright’s ISCO Form 4 transactions open-market buys or sells?

No. The Form 4 shows option grants classified as acquisitions under code A. These are awards from International Stem Cell, not open‑market purchases or sales, so they mainly reflect equity-based compensation rather than trading activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 08:31 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Don Wright

(Last) (First) (Middle)

C/O INTERNATIONAL STEM CELL CORP.

9745 BUSINESSPARK AVENUE

(Street)

SAN DIEGO CALIFORNIA 92131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
International Stem Cell CORP [ ISCO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.17	06/11/2026		A		30,000		(1)	06/11/2036	Common Stock	30,000	$0.00	30,000	D
Stock Option (Right to Buy)	$0.178	06/11/2026		A		182,584		(2)	06/11/2036	Common Stock	182,584	$0.00	182,584	D

Explanation of Responses:

1. The shares underlying such option shall vest on the earlier of (a) June 11, 2027, or (b) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant.

2. The shares underlying such option shall vest in equal quarterly increments through June 11, 2027, with the first increment vesting on September 11, 2026.

	/s/ Russell Kern, as Attorney-in-Fact	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)